MedTrace Logo

DUS on the Prescribing Indications for CPA/EE in 5 European Countries

NCT02494297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1597

Last updated 2021-08-27

Study results available
· View outcomes & findings →

Summary

This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including:

* prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
* use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
* concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
* second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne

Conditions

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Center for Epidemiology and Health Research, Germany

    lead OTHER

Principal Investigators

  • Klaas Heinemann, PhD, MD, MSc, MBA · Center for Epidemiology and Health Research Berlin

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-06
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02494297 on ClinicalTrials.gov